I’m dedicating a chapter in my next book to the psychedelic therapy industry, and the research for that chapter has brought me to the rise and sudden collapse of psychedelic research in the 1960s.


The typical cultural narrative goes like this: mid-century scientists discovered the profound therapeutic promise of substances like LSD and psilocybin, but a sudden wave of media-driven “moral panic” over counterculture hippies forced the U.S. government to criminalize them in 1968, shutting down legitimate science for decades.

This is both accurate and inaccurate. Public anxiety and sensationalized news coverage did indeed exploded in the late '60s; however, framing the shutdown of psychedelic research solely as a result of external "moral panic" misses a much more complex—and troubling—internal dynamic within the psychiatric establishment itself.

The Early Promise: Safe and Clinically Effective

In the 1950s and early 1960s, chemists and psychiatrists viewed psychedelics as cutting-edge tools in mainstream psychiatric research. Extensive clinical studies demonstrated that LSD and psilocybin were non-toxic, non-addictive, and safe when administered under medical supervision. Sidney Cohen’s landmark 1960 study concluded that serious adverse physical or psychological reactions were remarkably rare with proper precautions (see Novak 1997).

Clinically, the data supported their utility:

  • Addiction: LSD-assisted psychotherapy demonstrated roughly 50% success rates in treating severe alcohol dependence.
  • End-of-Life Care: Pioneered by Dr. Eric Kast, LSD showed dramatic success in relieving severe pain, anxiety, and the existential fear of death in terminally ill cancer patients.
  • Mystical & Creative States: Experiments like the 1962 Good Friday Experiment and Harman et al.’s 1966 trial highlighted psilocybin’s ability to produce (entice? reveal?) profound spiritual experiences and enhance creative problem-solving.

If the evidence was so strong, why did the medical community turn its back?


The Disenchantment of Psychiatry

Long before Congress passed prohibition laws, the medical establishment was already retreating from psychedelic medicine. Scientific, methodological, and institutional friction drove this shift:

  1. Methodological Incompatibility: In 1962, tighter FDA regulations established double-blinded, placebo-controlled trials as the “gold standard” for drug approval. Because the subjective effects of high-dose psychedelics are impossible to blind, researchers struggled to fit psychedelic-assisted therapy into standard pharmaceutical frameworks.
  2. Professional Paradigm Clashes: To mid-century psychiatrists, the core phenomena produced by psychedelics—hallucinations, ego dissolution, and sudden emotional volatility—resembled symptoms of acute mental illness, not cure. The idea that temporarily inducing a psychotic-like state could lead to lasting psychological healing ran counter to prevailing psychiatric models.
  3. Safety Concerns and Post-Hoc Fallacies: Early associations with CIA and military research (such as Project MK-Ultra, which framed LSD as an agent of psychosis and terror) laid a foundation of institutional anxiety. As recreational use spread, emergency room visits for “bad trips” led figures like National Institute of Mental Health Director Dr. Stanley Yolles to label LSD “chemical Russian roulette,” while unsubstantiated claims regarding genetic damage further eroded professional confidence.
  4. Unconventional Figureheads: The field was increasingly linked to unguided experimentation and controversial mavericks, making mainstream researchers eager to distance themselves to protect their academic reputations.


The Anti-Drug Moral Lens

When Congress moved to criminalize psychedelics in 1968, lawmakers were stepping into a vacuum left by an establishment that had already abandoned the field.


Entrenched in a long-standing prohibitionist moral framework—one that equated non-medical altered states of consciousness with a loss of productivity and moral failing—politicians viewed the lack of unanimous medical endorsement as a green light. Without strong advocacy from mainstream psychiatry to protect these research protocols, psychedelics were placed in Schedule I, erasing decades of clinical knowledge.


The Corporate Renaissance: “Buy the Ticket, Take the Ride”

As we live through a modern resurgence of psychedelic science—with FDA breakthrough designations, clinical trials for PTSD and depression, and growing public interest—it is tempting to celebrate the return of these ancient molecules. However, the modern landscape introduces a commercial dynamic that was absent during the initial 1960s research boom: corporate ownership and aggressive monetization.


Today, the clinical re-entry of psychedelics is heavily driven by private capital, intellectual property claims, and corporate patents on chemical formulations or treatment protocols. We cannot ignore this money-making dimension. In a sense, Hunter S. Thompson’s famous maxim, “Buy the ticket, take the ride,” takes on a distinctly literal and commodified meaning in 21st-century psychiatry.

In this new paradigm, the seller of the ticket is no longer a countercultural guru or a university clinician, but a corporate entity holding patented rights to a standardized alter-state experience. This raises a profound question about what is actually being bought and sold:

  • Is corporate psychiatry marketing genuine, durable healing?
  • Or are these proprietary molecules selling a form of sanitized, highly regulated psychedelic tourism—a pre-packaged, high-priced transactional journey designed to produce repeatable revenue streams rather than fundamental personal or systemic transformation?
  • Even when personal, individual transformation takes place, does the social landscape create the possibility of consolidating that transformation and helping individuals develop their insights into long-lasting life practice?


When financial conflicts of interest align with clinical incentives, the pressure to exaggerate efficacy and downplay adverse outcomes becomes acute. Whereas “adverse outcomes” were connected with 1950s moral scare tactics about insanity, these outcomes today are the produce of social frictions that therapists almost always sidestep as they seek novel ways of “curing” mental illness. Additionally, if access to therapeutic “trips” is mediated entirely by patent holders, we risk replacing the old prohibitionist moralism with a boutique medical marketplace that prioritizes profit margins over broad public accessibility and scientific transparency.


SOURCES:


Cover Photo comes from: https://www.flickr.com/photos/lab604/3333506218 and is used here as part of the creative commons license: https://creativecommons.org/licenses/by-nc-sa/2.0/


Harman, W. W., McKim, R. H., Mogar, R. E., Fadiman, J., & Stolaroff, M. J. 1966. “Psychedelic Agents in Creative Problem-Solving: A Pilot Study.” Psychological Reports, 19(1): 211–227. https://doi.org/10.2466/pr0.1966.19.1.211


Novak, Steven J. 1997. “LSD before Leary: Sidney Cohen's Critique of 1950s Psychedelic Drug Research.” Isis 99(1): 87–110. https://doi.org/10.1086/383628